Patents Examined by Catherine S Hibbert
  • Anti-tumor therapy
    Patent number: 10421971
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: September 24, 2019
    Inventors: Liufu Deng, Yang-xin Fu, Nikolai Khodarev, Ralph Weichselbaum
  • Recombinant vectors
    Patent number: 10407666
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: September 10, 2019
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Use of microvesicles in analyzing nucleic acid profiles
    Patent number: 10407728
    Abstract: The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 10, 2019
    Assignee: The General Hospital Corporation
    Inventors: Mikkel Noerholm, Johan Karl Olov Skog, Xandra O. Breakefield, Bob Carter
  • Method of screening a drug such as insulin secretagogue
    Patent number: 10393732
    Abstract: The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 27, 2019
    Assignee: JNC Corporation
    Inventor: Satoshi Inouye
  • Multiplexed genome editing
    Patent number: 10375938
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: August 13, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell
  • Viral resistant cells and uses thereof
    Patent number: 10377990
    Abstract: The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: August 13, 2019
    Assignee: SIgma-Aldrich Co. LLC
    Inventors: Nan Lin, Joaquina Mascarenhas, Audrey Chang, David Onions, Henry George, Kevin Kayser
  • Processes and host cells for genome, pathway, and biomolecular engineering
    Patent number: 10370654
    Abstract: The present disclosure provides compositions and methods for genomic engineering.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 6, 2019
    Assignee: enEvolv, Inc.
    Inventors: Jay H. Konieczka, James E. Spoonamore, Ilan N. Wapinski, Farren J. Isaacs, Gregory B. Foley
  • Cell-based assay for determining mTOR activity
    Patent number: 10351609
    Abstract: Disclosed are methods of determining activity of mTOR variants upon exposure to mTOR inhibitors, such a rapamycin or rapalogs thereof, methods for determining kinase activity of a mTOR variant, and methods for determining tumor cell response to treatment with rapamycin or rapalogs thereof. A method for determining whether a compound inhibits mTOR activity in a cell is also disclosed.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 16, 2019
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Elisa A Waxman, Thais Acquafreda
  • Engineered cascade components and cascade complexes
    Patent number: 10329547
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 25, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Dual cistronic bacterial expression system
    Patent number: 10329571
    Abstract: The present invention relates to the dual, independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria E. coli. The present invention also provides the process for the expression of protein of interest using said bicistronic vector.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: June 25, 2019
    Assignee: Lupin Limited
    Inventors: Shardul Salunkhe, Brajesh Varshney, Sudheerbabu Soorapaneni
  • Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
    Patent number: 10329587
    Abstract: Methods of modulating expression of a target nucleic acid in a cell are provided including use of multiple orthogonal Cas9 proteins to simultaneously and independently regulate corresponding genes or simultaneously and independently edit corresponding genes.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: June 25, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Kevin M. Esvelt, Prashant G. Mali
  • Method for detecting DLX1 mRNA, HOXC6 mRNA, and KLK3 mRNA in a urine sample and predicting and treating clinically significant prostate cancer
    Patent number: 10329625
    Abstract: The present invention relates to methods, devices, combinations, kits, and systems for predicting and treating clinically significant prostate cancer in a urine sample of an individual suspected of suffering from prostate cancer based on expression analysis of normalized prostate tumor markers. The present methods, devices, combinations, kits, and systems are especially suitable for predicting and treating prostate cancer with a Gleason score of seven or more in individuals with a serum prostate-specific antigen (sPSA) level lower than 15 ng/ml.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 25, 2019
    Assignee: MDxHealth Research B.V.
    Inventors: Daphne Hessels, Franciscus Petrus Smit, Jack A. Schalken
  • CRISPR-based methods and products for increasing frataxin levels and uses thereof
    Patent number: 10323073
    Abstract: Methods and products (e.g., gRNAs, recombinant fusion proteins, frataxin targeting systems, compositions and kits) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jacques P. Tremblay, Pierre Chapdelaine, Joël Rousseau
  • Early post-transfection isolation of cells (EPIC) for biologics production
    Patent number: 10317329
    Abstract: Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 11, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Victor R. Cairns, Christine DeMaria, Jason Vitko
  • Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
    Patent number: 10301650
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 28, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Method of increasing the function of an AAV vector
    Patent number: 10301648
    Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: May 28, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Luk Vandenberghe, Guangping Gao, James M. Wilson
  • Methods for selecting protease resistant polypeptides
    Patent number: 10302655
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Glaxo Group Limited
    Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
  • Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
    Patent number: 10293056
    Abstract: The present invention relates to non-viral gene therapy methods and compositions for treatment of hyperproliferative disease in humans. More specifically, the invention is directed, in one embodiment, to lipid formulations which form stable liposome structures, capable of efficient in vivo nucleic acid transfer. In other embodiments, methods and compositions are directed to liposome transfer of anti-proliferative nucleic acids, wherein the transfer of the nucleic acids is cell specific via cell specific targeting moieties. The present invention, thus provides non-viral, liposome compositions and methods of gene transfer particularly useful for targeting and treating hyperproliferative disease.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: May 21, 2019
    Assignees: Board of Regents, The University of Texas System, Introgen Research Institute, Inc.
    Inventors: Rajagopal Ramesh, Jack A. Roth, Tomoyuki Saeki, Deborah R. Wilson
  • Filamentous fungus mutant strain and use thereof
    Patent number: 10287593
    Abstract: A filamentous fungus mutant strain in which enzyme production inhibition caused by glucose is suppressed is constructed, and a method of producing a polysaccharide-degrading enzyme, a method of producing a saccharide from biomass, and a method of saccharifying biomass, each using the filamentous fungus, are provided. The filamentous fungus mutant strain in which Sre1 expression is reduced compared to a parent strain or is lost.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 14, 2019
    Assignee: Kao Corporation
    Inventors: Toshiharu Arai, Hiroshi Kakeshita
  • Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system
    Patent number: 10280419
    Abstract: Methods and products are described related to use of the CRISPR/Cas9 system to introduce a modification into an APP gene, such as guide RNAs and recombinant proteins, for decreasing amyloid beta peptide produced by a cell. Also described are uses of such methods and products for the treatment of Alzheimer's disease and/or age-related cognitive decline in a cell from a subject in need thereof.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: May 7, 2019
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jacques P. Tremblay, Joël Rousseau, Pierre Chapdelaine